Veracyte, Inc. (VCYT) DCF Valuation

Veracyte, Inc. (VCYT) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Veracyte, Inc. (VCYT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Save time and improve precision with our (VCYT) DCF Calculator! With real Veracyte data and customizable assumptions, this tool enables you to forecast, analyze, and value Veracyte, Inc. like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 120.4 117.5 219.5 296.5 361.1 488.6 661.2 894.7 1,210.8 1,638.5
Revenue Growth, % 0 -2.4 86.85 35.09 21.76 35.32 35.32 35.32 35.32 35.32
EBITDA -7.8 -25.8 -60.2 -7.0 -49.4 -70.2 -95.0 -128.6 -174.1 -235.5
EBITDA, % -6.49 -21.94 -27.42 -2.35 -13.68 -14.38 -14.38 -14.38 -14.38 -14.38
Depreciation 4.1 8.9 21.2 29.2 27.2 37.2 50.3 68.1 92.2 124.7
Depreciation, % 3.42 7.58 9.67 9.86 7.53 7.61 7.61 7.61 7.61 7.61
EBIT -11.9 -34.7 -81.4 -36.2 -76.6 -107.4 -145.4 -196.7 -266.2 -360.3
EBIT, % -9.9 -29.52 -37.09 -12.22 -21.22 -21.99 -21.99 -21.99 -21.99 -21.99
Total Cash 159.3 349.4 173.2 178.9 216.5 390.1 527.8 714.3 966.6 1,308.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 19.3 18.5 41.5 44.0 40.4
Account Receivables, % 16.06 15.71 18.89 14.85 11.18
Inventories 6.8 4.7 11.2 14.3 16.1 23.5 31.8 43.0 58.2 78.7
Inventories, % 5.65 3.96 5.11 4.82 4.47 4.8 4.8 4.8 4.8 4.8
Accounts Payable 2.3 3.1 12.4 11.9 12.9 17.4 23.6 31.9 43.1 58.4
Accounts Payable, % 1.93 2.65 5.63 4.02 3.58 3.56 3.56 3.56 3.56 3.56
Capital Expenditure -2.8 -2.8 -5.4 -8.5 -10.0 -12.5 -16.9 -22.9 -31.0 -41.9
Capital Expenditure, % -2.29 -2.41 -2.45 -2.88 -2.76 -2.56 -2.56 -2.56 -2.56 -2.56
Tax Rate, % 2.88 2.88 2.88 2.88 2.88 2.88 2.88 2.88 2.88 2.88
EBITAT -15.6 -35.6 -75.3 -36.4 -74.4 -105.2 -142.4 -192.7 -260.7 -352.8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -38.0 -25.7 -79.8 -21.7 -54.3 -118.0 -137.6 -186.2 -251.9 -340.9
WACC, % 12.29 12.29 12.29 12.29 12.29 12.29 12.29 12.29 12.29 12.29
PV UFCF
SUM PV UFCF -695.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -348
Terminal Value -3,380
Present Terminal Value -1,893
Enterprise Value -2,588
Net Debt -204
Equity Value -2,385
Diluted Shares Outstanding, MM 73
Equity Value Per Share -32.82

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real Veracyte, Inc. (VCYT) financials.
  • Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe how your inputs affect Veracyte, Inc. (VCYT)’s valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, with comprehensive step-by-step instructions.

Key Features

  • Comprehensive Veracyte Financials: Gain access to precise pre-loaded historical data and future forecasts.
  • Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • Interactive Dashboard: User-friendly charts and summaries to illustrate your valuation outcomes.
  • Designed for All Levels: An easy-to-navigate structure tailored for investors, CFOs, and consultants alike.

How It Works

  • 1. Download the Template: Acquire and open the Excel file featuring Veracyte, Inc.'s preloaded data.
  • 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures to fit your analysis.
  • 3. View Results in Real-Time: The DCF model automatically computes intrinsic value and NPV based on your inputs.
  • 4. Explore Different Scenarios: Evaluate various forecasts to assess different valuation possibilities.
  • 5. Present with Assurance: Share professional valuation findings to bolster your strategic decisions.

Why Choose This Calculator for Veracyte, Inc. (VCYT)?

  • User-Friendly Interface: Perfect for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to fit your specific analysis needs.
  • Real-Time Feedback: Observe immediate updates to Veracyte’s valuation as you tweak inputs.
  • Pre-Configured Data: Comes with Veracyte’s actual financial metrics for swift evaluation.
  • Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Healthcare Investors: Develop comprehensive and accurate valuation models for Veracyte, Inc. (VCYT) analysis.
  • Biotech Finance Teams: Assess valuation scenarios to inform strategic decisions within the organization.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Veracyte, Inc. (VCYT).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Life Sciences Enthusiasts: Gain insights into how biotech companies like Veracyte, Inc. (VCYT) are valued in the marketplace.

What the Template Contains

  • Pre-Filled DCF Model: Veracyte, Inc.’s (VCYT) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Veracyte, Inc.’s (VCYT) profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.